UK multiple sclerosis risk-sharing scheme: A new natural history dataset and an improved Markov model

BMJ Open

Volumn 4, Issue 1, 2014, Pages

  Palace, Jacqueline ^a   Bregenzer, Thomas ^b   Tremlett, Helen ^c   Oger, Joel ^c   Zhu, Fheng ^c   Boggild, Mike ^d   Duddy, Martin ^e   Dobson, Charles ^f  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b PAREXEL INTERNATIONAL   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d TOWNSVILLE HOSPITAL   (Australia)

^e NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f Department of Health ^*  (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; COST; DATA BASE; EXPANDED DISABILITY STATUS SCALE; HIDDEN MARKOV MODEL; HUMAN; MEDICAL HISTORY; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT SELECTION; PROBABILITY; REVIEW; UNITED KINGDOM; ADOLESCENT; ADULT; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; INFORMATION PROCESSING; MALE; MIDDLE AGED; PROSPECTIVE STUDY; RISK; RISK MANAGEMENT; STATISTICAL MODEL; YOUNG ADULT;

ADOLESCENT; ADULT; CANADA; COST-BENEFIT ANALYSIS; DATASETS AS TOPIC; FEMALE; GREAT BRITAIN; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, STATISTICAL; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; RISK; RISK SHARING, FINANCIAL; YOUNG ADULT;

EID: 84892884652     PISSN: None     EISSN: 20446055     Source Type: Journal    
DOI: 10.1136/bmjopen-2013-004073     Document Type: Review

References (28)

1. National Institute for Health and Care Excellence. Beta interferon and glatiramer acetate for the treatment of multiple sclerosis. NICE Technology Appraisal Guidance No. 32. London: NICE, 2002.
2. Department of Health. Cost effective provision of disease modifying therapies for people with multiple sclerosis. London: Health Service Circular 2002/004 London: Stationery Office, 2002.
3. Chilcott J, McCabe C, Tappenden P, et al. Modelling the cost-effectiveness of interferon beta and glatiramer acetate in the management of multiple sclerosis. BMJ 2003;326:522.
4. Hemmett L, Holmes J, Barnes M, et al. What drives quality of life in multiple sclerosis? QJM 2004;97:671-6. (Pubitemid 39359325)
5. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life in multiple sclerosis. A cross-sectional observational study in the UK. Scandinavian Working Papers in Economics, 2000. http://swopec. hhs.se/hastef/papers/hastef0398.pdf (accessed 28 Aug 2013).
6. Boggild M, Palace J, Barton P, et al. Multiple sclerosis risk sharing scheme: two year results of clinical cohort study with historical comparator. BMJ 2009;339:b4677.
7. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
8. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94. (Pubitemid 26100751)
9. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504.
10. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995;45:1268-76.
11. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352:1491-7.
12. Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504.
13. Tremlett H, Paty D, Devonshire V. Disability progression in MS is slower than previously reported. Neurology 2006;66:172-7. (Pubitemid 43970148)
14. Tremlett H, Zhao Y, Rieckmann P, et al. New perspectives in the natural history of multiple sclerosis. Neurology 2010; 74:2004-15.
15. Sadovnick AD, Ebers GC, Wilson RW, et al. Life expectancy in patients attending multiple sclerosis clinics. Neurology 1992;42:991-4.
16. Sweeney VP, Sadovnick AD, Brandejs V. Prevalence of multiple sclerosis in British Columbia. Can J Neurol Sci 1986;13:47-51. (Pubitemid 16189888)
17. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31. (Pubitemid 13158528)
18. Craig BA, Sendi PP. Estimation of the transition matrix of a discrete-time Markov chain. Health Econ 2002;11:33-42. (Pubitemid 34097620)
19. Jackson CH, Sharples LS, Thompson SG, et al. Multistate Markov models for disease progression with classification error. J R Stat Soc 2003;52:193-209. (Pubitemid 37268398)
20. Roxburgh RH, Seaman SR, Masterman T, et al. Multiple Sclerosis Severity Score: using disability and disease duration to rate disease severity. Neurology 2005;64:1144-51.
21. Albert P. A Markov model for sequences of ordinal data from a relapsing-remitting disease. Biometrics 1994;50:51-60. (Pubitemid 24138573)
22. Bell C, Graham J, Earnshaw S, et al. Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data. J Manag Care Pharm 2007;13:245-61. (Pubitemid 46730893)
23. Mandel M, Betensky R. Estimating time-to-event from longitudinal ordinal data using random-effects Markov models: application to multiple sclerosis progression. Biostatistics 2008;9:750-64.
24. Shirani A, Zhao Y, Kingwell E, et al. Temporal trends of disability progression in multiple sclerosis: findings from British Columbia, Canada (1975-2009). Mult Scler 2012;18:442-50.
25. Shirani A, Zhao Y, Karim ME, et al. Association between use of interferon beta and progression of disability in patients with relapsing-remitting multiple sclerosis. JAMA 2012;308:247-56.
26. http://www.bcstats.gov.bc.ca/StatisticsBySubjct/Census.aspx Specifically the 1986 Census.
27. Lourenco P, Shirani J, Saeedi J, et al. Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis associations with disease course and progression. Mult Scler J 2013; 19:577-84.
28. http://www.msif.org/includes/documents/cm-docs/2013/m/ msif-atlas-of-ms-2013-report.pdf?f=1